Hints and tips:
...Fresenius had hired lawyers to investigate their ability to exit Akorn....
...Shares in US generic drugmaker Akorn dropped 21 per cent on Friday after a US court upheld its decision to allow Germany’s Fresenius to walk away from a $4.8bn takeover of the company....
...Project Oak was the code name Akorn adopted as it negotiated with Fresenius....
...Akorn disagreed with the findings and filed a lawsuit alleging wrongful termination of the deal....
...For Illinois-based Akorn, the deal’s collapse is just the latest in a series of unfortunate events....
...investors in UK (FT) Pound exodus: Brexit drives away US and Asia investors (FT) ‘Mergers of the middle’ propel fund industry M&A past $21bn (FT) Brexit damps private equity appetite for UK deals (FT) Akorn...
...Akorn shares had rallied 18 per cent earlier this month when Fresenius confirmed that it was in talks to buy Akorn....
...potential acquisition of Akorn, Inc....
...If successful, the ploy would close down one route used by generic drugmakers, such as Teva Pharmaceuticals, Mylan and Akorn, which are trying to have Allergan’s intellectual property invalidated so they...
International Edition